High monocyte count and expression of s100a9 and s100a12 in peripheral blood mononuclear cells are associated with poor outcome in patients with metastatic prostate cancer
| Autor: | Elin Thysell, Lee-Ann Tjon-Kon-Fat, Jonas Nilsson, Anna-Maja Åberg, Camilla Thellenberg-Karlsson, Marie Lundholm, Anders Widmark, Pernilla Wikström, Anders Bergh, Sofia Halin Bergström |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Inflammation Metastases S100 protein Peripheral blood mononuclear cell Monocytes Androgen deprivation therapy 03 medical and health sciences Prostate cancer 0302 clinical medicine Internal medicine medicine Progression-free survival Prospective cohort study metastases S100A9 RC254-282 Cancer och onkologi business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease prostate cancer peripheral blood mononuclear cells 030104 developmental biology Tumor progression S100A12 030220 oncology & carcinogenesis Peripheral blood mononuclear cells Cancer and Oncology medicine.symptom business monocytes |
| Zdroj: | Cancers, Vol 13, Iss 2424, p 2424 (2021) Cancers Volume 13 Issue 10 |
| Popis: | Increasing evidence indicates calcium-binding S100 protein involvement in inflammation and tumor progression. In this prospective study, we evaluated the mRNA levels of two members of this family, S100A9 and S100A12, in peripheral blood mononuclear cells (PBMCs) in a cohort of 121 prostate cancer patients using RT-PCR. Furthermore, monocyte count was determined by flow cytometry. By stratifying patients into different risk groups, according to TNM stage, Gleason score and PSA concentration at diagnosis, expression of S100A9 and S100A12 was found to be significantly higher in patients with metastases compared to patients without clinically detectable metastases. In line with this, we observed that the protein levels of S100A9 and S100A12 in plasma were higher in patients with advanced disease. Importantly, in patients with metastases at diagnosis, high monocyte count and high levels of S100A9 and S100A12 were significantly associated with short progression free survival (PFS) after androgen deprivation therapy (ADT). High monocyte count and S100A9 levels were also associated with short cancer-specific survival, with monocyte count providing independent prognostic information. These findings indicate that circulating levels of monocytes, as well as S100A9 and S100A12, could be biomarkers for metastatic prostate cancer associated with particularly poor prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|